Eli Lilly and Company (LLY) and EVA Pharma announced on Wednesday their collaboration to broaden the availability of baricitinib to residents of 49 low- to middle-income countries in Africa by 2030.
Baricitinib, initially discovered by Incyte and licensed to Lilly, has received approval for the treatment of rheumatoid arthritis, alopecia areata, atopic dermatitis, and COVID-19.
Under this agreement, Lilly will transfer certain manufacturing know-how for baricitinib to EVA Pharma, enabling them to produce and distribute the medication across the specified African nations.
This partnership aligns with Lilly's 30x30 initiative, which aspires to enhance access to quality healthcare for 30 million individuals in resource-limited settings each year by 2030. The companies have been collaboratively pursuing this mission since 2021.
Additionally, as revealed in 2022, Lilly and EVA Pharma are working together to supply affordable insulin to 56 countries, primarily targeting low- to middle-income nations.
